MA51135A - Anticorps anti-alpha-synucléine - Google Patents

Anticorps anti-alpha-synucléine

Info

Publication number
MA51135A
MA51135A MA051135A MA51135A MA51135A MA 51135 A MA51135 A MA 51135A MA 051135 A MA051135 A MA 051135A MA 51135 A MA51135 A MA 51135A MA 51135 A MA51135 A MA 51135A
Authority
MA
Morocco
Prior art keywords
alpha
synuclein antibody
synuclein
antibody
Prior art date
Application number
MA051135A
Other languages
English (en)
Inventor
Ralph Adams
Terence Seward Baker
Lichtervelde Lorenzo De
Patrick Downey
Daniel John Lightwood
David James Mcmillan
Kerry Louise Tyson
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA51135A publication Critical patent/MA51135A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA051135A 2017-12-15 2018-12-13 Anticorps anti-alpha-synucléine MA51135A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720975.0A GB201720975D0 (en) 2017-12-15 2017-12-15 Anti-alpha synuclein antibodies

Publications (1)

Publication Number Publication Date
MA51135A true MA51135A (fr) 2021-03-24

Family

ID=61009086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051135A MA51135A (fr) 2017-12-15 2018-12-13 Anticorps anti-alpha-synucléine

Country Status (26)

Country Link
US (2) US11261242B2 (fr)
EP (1) EP3724224A1 (fr)
JP (2) JP7292279B2 (fr)
KR (1) KR102789446B1 (fr)
CN (1) CN111479826B (fr)
AR (1) AR115192A1 (fr)
AU (1) AU2018382530B2 (fr)
BR (1) BR112020010504A2 (fr)
CA (1) CA3083199A1 (fr)
CL (1) CL2020001605A1 (fr)
EA (1) EA202091478A1 (fr)
EC (1) ECSP20039623A (fr)
GB (1) GB201720975D0 (fr)
IL (1) IL275187B2 (fr)
MA (1) MA51135A (fr)
MX (2) MX2020005691A (fr)
MY (1) MY205948A (fr)
PE (1) PE20201061A1 (fr)
PH (1) PH12020551007A1 (fr)
SG (1) SG11202004502SA (fr)
TN (2) TN2021000169A1 (fr)
TW (2) TWI801469B (fr)
UA (1) UA126295C2 (fr)
UY (1) UY38010A (fr)
WO (1) WO2019115674A1 (fr)
ZA (2) ZA202003542B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
WO2021055881A1 (fr) * 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anticorps anti-alpha-synucléine et leurs procédés d'utilisation
US20230025256A1 (en) * 2019-12-04 2023-01-26 Simon Friedman Protein blocking assembly and methods of making and using
KR20240176098A (ko) * 2023-06-14 2024-12-24 경상국립대학교산학협력단 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2002050121A1 (fr) 2000-12-13 2002-06-27 Taisho Pharmaceutical Co.,Ltd. Nouvel anticorps
EP1572894B1 (fr) 2001-11-21 2016-04-13 New York University Polypeptides immunogènes synthétiques ne formant pas de dépôts et peptides homologues déstinés à des répétitions amyloide beta, protéine prion, amyline, alpha-synucléine, ou polyglutamine pour induction d'une réponse immunitaire à ceux-ci
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (fr) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Anticorps a l'alpha-synucleine
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CA2657953A1 (fr) 2005-07-19 2007-01-25 University Of Rochester Anticorps d'alpha-synucleine et techniques associees
WO2007021255A1 (fr) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Anticorps de l’alpha-synucléine
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
LT3067066T (lt) 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
ES2709048T3 (es) 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2366714A1 (fr) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Auto-anticorps d'origine naturelle contre l'alpha-synucléine qui inhibent l'agrégation et la cytotoxicité de l'alpha-synucléine
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
EP2771031B1 (fr) * 2011-10-28 2018-04-18 Prothena Biosciences Limited Anticorps humanisés qui reconnaissent l'alpha-synucléine
EP2807188B1 (fr) 2012-01-27 2019-09-11 Prothena Biosciences Limited Anticorps humanisés qui reconnaissent l'alpha-synucléine
WO2013173827A2 (fr) 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Procédés et compositions pour inhiber des maladies du système nerveux central
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015179867A1 (fr) 2014-05-23 2015-11-26 University Of South Florida Procédés, anticorps, et vaccins utilisant des épitopes d'alpha synucléine pour le traitement de la maladie de parkinson
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
EP3191599B1 (fr) 2014-09-11 2023-08-02 Board Of Regents Of the University Of Texas System Détection de protéines mal-repliées
WO2016040903A1 (fr) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Détection de protéine bêta amyloïde à repliement incorrect
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JP6989927B2 (ja) 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法
EP3380622A4 (fr) 2015-11-23 2019-08-07 Sangamo Therapeutics, Inc. Méthodes et compositions pour modifier l'immunité
WO2017176835A2 (fr) 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Anticorps thérapeutiques pour le traitement de la neurodégénérescence
TW202309093A (zh) 2016-06-02 2023-03-01 英商梅迪繆思有限公司 針對α-突觸核蛋白之抗體及其用途
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
US20190194324A1 (en) 2016-08-23 2019-06-27 The Johns Hopkins University THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
US20180134777A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (11D12)
US20180134776A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (4H6)
US20180134775A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
EP3551228A4 (fr) 2016-12-12 2020-08-12 The Michael J. Fox Foundation For Parkinson's Research Anticorps dirigés contre l'alpha-synucléine humaine
EP3555127B1 (fr) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, utilisations et procédés
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018128454A1 (fr) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 ANTICORPS ANTI-α-SYN ET SON UTILISATION
JP2020504151A (ja) 2017-01-09 2020-02-06 カリフォルニア インスティチュート オブ テクノロジー パーキンソン病の診断および治療薬における腸内微生物叢の使用
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
KR20200007945A (ko) 2017-05-16 2020-01-22 암프리온, 인코퍼레이티드 미스폴딩된 타우 단백질의 검출
WO2018237338A1 (fr) 2017-06-23 2018-12-27 Denali Therapeutics Inc. Anticorps anti-alpha-synucléine et leurs procédés d'utilisation
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
TN2021000169A1 (en) 2023-04-04
JP2021509012A (ja) 2021-03-18
IL275187B1 (en) 2026-01-01
RU2020123274A3 (fr) 2022-01-17
EP3724224A1 (fr) 2020-10-21
ECSP20039623A (es) 2020-08-31
TN2020000069A1 (en) 2022-01-06
CN111479826A (zh) 2020-07-31
EA202091478A1 (ru) 2020-09-04
CA3083199A1 (fr) 2019-06-20
ZA202003542B (en) 2022-12-21
CL2020001605A1 (es) 2020-08-28
IL275187A (en) 2020-07-30
TWI801469B (zh) 2023-05-11
UY38010A (es) 2019-07-31
TW201930354A (zh) 2019-08-01
US20220220192A1 (en) 2022-07-14
BR112020010504A2 (pt) 2020-11-24
AU2018382530A1 (en) 2020-06-18
WO2019115674A1 (fr) 2019-06-20
US20210107971A1 (en) 2021-04-15
JP7292279B2 (ja) 2023-06-16
KR102789446B1 (ko) 2025-04-01
SG11202004502SA (en) 2020-06-29
US12545720B2 (en) 2026-02-10
MX2024013356A (es) 2024-12-06
MY205948A (en) 2024-11-21
KR20200099160A (ko) 2020-08-21
JP2023127585A (ja) 2023-09-13
PE20201061A1 (es) 2020-10-16
CN111479826B (zh) 2024-10-29
UA126295C2 (uk) 2022-09-14
ZA202103456B (en) 2023-01-25
RU2020123274A (ru) 2022-01-17
JP7627300B2 (ja) 2025-02-05
GB201720975D0 (en) 2018-01-31
IL275187B2 (en) 2026-05-01
AR115192A1 (es) 2020-12-09
MX2020005691A (es) 2020-08-20
PH12020551007A1 (en) 2021-08-16
TW202332692A (zh) 2023-08-16
US11261242B2 (en) 2022-03-01
AU2018382530B2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
MA49034A (fr) Anticorps anti-lag3
MA47694A (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
FR25C1022I2 (fr) Anticorps anti-pd-1
EP3498840A4 (fr) Anticorps anti-lag-3
EP3423089A4 (fr) Anticorps anti-tigit
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
MA46041A (fr) Anticorps anti-tim -3
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA50352A (fr) Anticorps multispécifiques
MA49749A (fr) Anticorps anti-cd137
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3526247A4 (fr) Anticorps anti-il1-rap
MA52152A (fr) Anticorps
EP3383915A4 (fr) Anticorps anti-pd-1
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde